...
首页> 外文期刊>Transfusion: The Journal of the American Association of Blood Banks >Automatic interface-controlled apheresis collection of stem/progenitor cells: results from an autologous donor validation trial of a novel stem cell apheresis device.
【24h】

Automatic interface-controlled apheresis collection of stem/progenitor cells: results from an autologous donor validation trial of a novel stem cell apheresis device.

机译:界面自动控制的干/祖细胞单采血液收集:一种新型干细胞单采血液分离设备的自体供体验证试验的结果。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Cryopreserved hematopoietic progenitor cells collected by apheresis from granulocyte-colony-stimulating factor with or without chemotherapy-mobilized patients have become the preferred type of autograft to support treatment of diseases amenable to high-dose chemotherapy. A novel apheresis system, the Spectra Optia v.5.0 (CaridianBCT), was constructed to meet certain shortcomings of manual apheresis systems such as the COBE Spectra MNC (CaridianBCT), including the need for continuous optical or manual monitoring and readjustment of buffy coat position and sensitivity to inconsistent blood flow. By use of optical sensors, which provide real-time automatic interface (buffy coat) and collection line control, the Spectra Optia promises to automatically guide apheresis procedures, potentially freeing up operator time and reducing variability in collection efficiency (CE2). STUDY DESIGN AND METHODS: In a two-center clinical trial, 35 autologous stem cell donors were subjected to apheresis with the Spectra Optia to validate feasibility and effectiveness of apheresis procedures. Results were compared to data from 80 autologous apheresis procedures with the COBE Spectra MNC. RESULTS: Usability and function of the automatic interface management were excellent. CD34+ cell quality, assessed by viability staining, colony-forming unit-culture frequency, and engraftment kinetics, was equally good with both systems. CE2 of the Spectra Optia, calculated as CD34+ contents in the product divided by the number of CD34+ cells presented to the collection port, exceeded that of the COBE Spectra MNC. Spectra Optia product volumes were significantly smaller. Very high white blood cell and platelet counts modestly reduced CE2 with the Spectra Optia. CONCLUSION: The Spectra Optia is a novel automatic apheresis system supporting autologous stem cell collection with at least equal efficiency and superior user-friendliness compared to the COBE Spectra MNC.
机译:背景:在有或没有化疗动员的情况下,通过单采血液分离术从粒细胞集落刺激因子中收集的冷冻保存的造血祖细胞已成为自体移植的首选类型,可支持治疗大剂量化疗所致的疾病。构造了一种新颖的单采血液分离系统Spectra Optia v.5.0(CaridianBCT),以解决手动单采血液分离系统的某些缺点,例如COBE Spectra MNC(CaridianBCT),包括需要连续光学或手动监控以及调整血沉棕黄层的位置对不稳定的血流敏感。通过使用提供实时自动界面(血沉棕黄层)和收集线控制的光学传感器,Spectra Optia有望自动引导血液分离程序,从而可能节省操作员时间并减少收集效率(CE2)的差异。研究设计和方法:在一个两中心的临床试验中,对35位自体干细胞供体进行了Spectra Optia血液分离术,以验证血液分离程序的可行性和有效性。将结果与使用COBE Spectra MNC进行的80例自体血液分离术的数据进行比较。结果:自动界面管理的可用性和功能非常出色。通过生存力染色,集落形成单位培养频率和移入动力学评估的CD34 +细胞质量在两个系统中均表现良好。以产品中CD34 +含量除以收集口中CD34 +细胞的数量计算得出的Spectra Optia的CE2超过了COBE Spectra MNC的CE2。 Spectra Optia产品的体积明显较小。使用Spectra Optia,极高的白细胞和血小板计数可适度降低CE2。结论:Spectra Optia是一种新颖的自动血液分离系统,与COBE Spectra MNC相比,它支持自体干细胞收集,效率至少相同,并且用户友好性更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号